Basu Sandip, Fargose Preeti
Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, India
Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, India.
J Nucl Med Technol. 2016 Dec;44(4):248-250. doi: 10.2967/jnmt.116.177873. Epub 2016 Sep 15.
The potential of peptide receptor radionuclide therapy (PRRT) is described in a case of recurrent inoperable phosphaturic mesenchymal tumor causing osteomalacia in the left basiocciput, for which the patient had undergone surgery twice previously. After one cycle of PRRT, there was good symptomatic improvement, with a modest reduction in uptake on both Ga-DOTATATE PET/CT and F-FDG PET/CT suggesting a favorable response. Hence, treatment with a second cycle was considered. Being somatostatin receptor-avid, this rare group of tumors when inoperable or recurrent may potentially be targeted with PRRT. Well-tolerated and noninvasive, PRRT could evolve as a promising targeted treatment approach in this clinical setting. In summary, tumor-induced osteomalacia with Ga-DOTATATE-avid inoperable or recurrent tumor can be considered a potential clinical application for PRRT beyond neuroendocrine tumors.
肽受体放射性核素治疗（PRRT）的潜力在一例复发性无法手术切除的致左枕骨基底部骨软化的磷尿性间叶肿瘤病例中得到了描述，该患者此前已接受过两次手术。在一个周期的PRRT治疗后，症状有明显改善，Ga-DOTATATE PET/CT和F-FDG PET/CT上的摄取均有适度降低，提示反应良好。因此，考虑进行第二个周期的治疗。由于这类罕见肿瘤对生长抑素受体有亲和力，当无法手术切除或复发时，PRRT可能对其有靶向作用。PRRT耐受性良好且无创，在这种临床情况下可能会发展成为一种有前景的靶向治疗方法。总之，对于Ga-DOTATATE亲和的无法手术切除或复发的肿瘤所致骨软化，PRRT可被视为神经内分泌肿瘤之外的一种潜在临床应用。
